Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer.

Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. Pancreatology. 2020 Jan; 20(1):101-109.

View in: PubMed